Gabexate is a serine protease inhibitor which is used therapeutically (as gabexate mesilate) in the treatment of pancreatitis, disseminated intravascular coagulation,[1] and as a regional anticoagulant for haemodialysis.[2]

Gabexate
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
  • none
Identifiers
  • ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H23N3O4
Molar mass321.377 g·mol−1
3D model (JSmol)
  • O=C(Oc1ccc(cc1)C(=O)OCC)CCCCC/N=C(\N)N
  • InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19) ☒N
  • Key:YKGYIDJEEQRWQH-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

References

edit
  1. ^ Yuksel M, Okajima K, Uchiba M, Okabe H (2003). "Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes". J. Pharmacol. Exp. Ther. 305 (1): 298–305. doi:10.1124/jpet.102.041988. PMID 12649382. S2CID 23518949.
  2. ^ Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V (1996). "Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group". N. Engl. J. Med. 335 (13): 919–23. doi:10.1056/NEJM199609263351302. PMID 8786777.